Clinical Oncology Research Program (CORP)

Case Western Reserve University, Cleveland OH

Investigators

Abstract

PROJECT SUMMARY/ABSTRACT The overall goal of the Clinical Oncology Research Program (CORP) is to support the intent of the Paul Calabresi Career Development Award for Clinical Oncology (K12). CORP fosters interdisciplinary training in clinical and translational oncology therapeutic research for early career faculty physicians (Assistant Professor) in one of a number of oncology disciplines, including medical, surgical, dermatologic, pediatric, radiation and pathology. By designing a K12 program that brings together these broad disciplines, the Paul Calabresi Scholars themselves form a multidisciplinary group whose collaborations and interactions augment the overall training efforts under the K12 program. The two-year training program with an option for a third year for Scholars who would benefit from additional training will support 4 Scholars a year. Firm core requirements include completion of required and elective course work for a Certificate in Clinical Translational Oncology Research at Case Western Reserve University. A basic research effort is a required part of the training program and is linked to the clinical research efforts that include writing and activating a therapeutic clinical protocol and submission of a career development award application. These efforts will result in highly qualified Paul Calabresi scholars capable of independent research in clinical oncology and therapeutics with a team science orientation based in hypothesis testing of important translational questions in the field. CORP brings together strong Internal and External Advisory Committee members committed and experienced in the area of clinical translational therapeutics research in oncology. CORP and the Case Comprehensive Cancer Center provides scholars with an outstanding environment to pursue career development. Past trainees have emerged as academic physicians developing independent clinical research programs often with external funding and with active investigator-initiated clinical trial efforts.